Clinique Saint-Pierre — Clinical Trial Site

49 Registered trials

23 Currently recruiting

Organisation

Clinique Saint-Pierre

Location

Ottignies-Louvain-La-Neuve, Belgium

Identifier

ORG-100044060

Address

Avenue Reine Fabiola 9, 1340, Belgium

Departments

#3101: Intensive Care
032011: Oncologie-Hématologie
Cardiovascular
General Oncology
Haematology
Hématologie
Hematology
ICU
Intensive Care
Intensive Care Unit
Internal Medicine/Oncology/Hematology
Medical Oncology
N/A
NA
Neurology Department
Oncologie
Oncologie - Hématologie
Oncologie médicale
Oncology
Oncology and Hematology
Oncology Department
Pneumology
Pneumology- Oncology
Soins Intensifs

Clinical trials at this site (49)

Search interface

CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting

2023-503317-29-00 Metastatic renal cell carcinoma (mRCC) 5 2024-04-12
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex… Recruiting

2024-514139-50-00 Multiple myeloma 5 2022-11-14
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
Safety and efficacy analysis of an antibody associated with a chemotherapy for patients with a triple negative metastatic breast cancer. Ended

2022-502369-10-00 Triple negative metastatic breast cancer 5 2023-10-02
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A study to test trimodulin in adult hospitalized patients with severe pneumonia Ended

2022-501352-28-00 Severe community-acquired pneumonia (sCAP) 5 2023-06-07
A study in metastatic breast cancer patients receiving eftilagimod alpha or placebo in combination with a standard chemotherapy (paclitaxel) Ended

2024-511023-34-00 HER2-neg/low metastatic breast cancer 10 2023-05-05
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin… Ended

2023-503467-41-00 Relapsed or Refractory Multiple Myeloma 5 2022-10-12
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2022-02-11
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended

2023-506986-74-00 B-cell non-Hodgkin lymphoma (NHL) 9 2021-12-27
A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended

2023-506365-64-00 Deleterious Germline or Somatic Homologous Recombinatio 5 2020-10-16
TALAPRO 2: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT… Ended

2023-509087-20-00 Metastatic Castration-resistant Prostate Cancer 5 2019-04-16
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Lo… Ended

2024-511850-34-00 Previously untreated locally recurrent inoperable or me 9 2019-01-02
A Phase 3 Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocyt… Ended

2023-509976-40-00 Untreated Chronic Lymphocytic Leukemia or Small Lymphoc 5 2018-05-28
A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Ended

2022-502798-40-00 Patients with resected colon carcinoma 5 2017-07-31
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended

2023-509671-17-00 Breast Cancer 5 2017-07-12
Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco… Ended

2024-516996-34-00 oestrogen-receptor (ER)-positive HER2-negative breast c 5 2012-04-12
Phase 2 Study of CAL02 plus Standard of Care in Severe Community-Acquired Bacterial Pneumonia (SCABP) Halted

2022-502049-91-00 SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP) 4 2023-09-26
Phase 2b study to investigate the safety and efficacy of TIN816 in SA-AKI Ended

2023-505903-22-00 Sepsis associated acute kidney injury 4 2024-07-02
A study to test trimodulin in adult hospitalized patients with CAP including COVID-19 pneumonia. Ended

2024-513002-60-00 Non-severe community-acquired pneumonia (CAP) or modera 5 2022-10-26
DESTINY-Breast08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other thera… Ended

2023-505690-33-00 Metastatic Breast Cancer 3 2022-03-11
The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic… Ended

2024-517251-12-00 Recurrent or metastatic head and neck squamous cell car 5 2021-11-02